CoChat

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists

Open access
Saraiva, Francisco Kerr, Sposito, Andrei C · 2014 · Cardiovascular Diabetology

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4× increased incidence of death from coronary artery disease. Patients with diabetes are considered for cardiovascular disease secondary prevention because their risk level is similar to that reported in patients without diabetes who have already suffered a myocardial infarction. More recently, with a better risk factors control, mainly in intensive LDL cholesterol targets with statins, a significant decrease in acute cardiovascular events was observed in population with diabetes. Together with other major risk factors, type 2 diabetes must be considered as an important cause of cardiovascular disease.Glucagon like peptide-1 receptor agonists represent a novel class of anti-hyperglycemic agents that have a cardiac-friendly profile, preserve neuronal cells and inhibit neuronal degeneration, an anti-inflammatory effect in liver protecting it against steatosis, increase insulin sensitivity, promote weight loss, and increase satiety or anorexia.This review is intended to rationally compile the multifactorial cardiovascular effects of glucagon-like peptide-1 receptor agonists available for the treatment of patients with type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-014-0142-7

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 GLP-1 is released from the small intestine after meal ingestion and enhance glucose-stimulated insulin secretion ( incretin action ). DPP-4 rapidly converts GLP-1 and GIP to their inactive metabolites in vivo. Inhibition of DPP-4 activity prevents GLP-1 and GIP degradation, thereby enhancing incretin action (Adapted from Abrahamson MJ. The increting effect of GLP-1. Diabetes, Cardiovascular Disease and Stroke: Mechanisms and Risk Reduction. http://www.medscape.org/viewarticle/557239 and reference [14]).
Figure 1 GLP-1 is released from the small intestine after meal ingestion and enhance glucose-stimulated insulin secretion ( incretin action ). DPP-4 rapidly converts GLP-1 and GIP to their inactive metabolites in vivo. Inhibition of DPP-4 activity prevents GLP-1 and GIP degradation, thereby enhancing incretin action (Adapted from Abrahamson MJ. The increting effect of GLP-1. Diabetes, Cardiovascular Disease and Stroke: Mechanisms and Risk Reduction. http://www.medscape.org/viewarticle/557239 and reference [14]).CC BY · PubMed Central
Figure 2 Pleitropic effects of GLP-1 or GLP-1R agonists (Adapted from references [ 24 ] ).
Figure 2 Pleitropic effects of GLP-1 or GLP-1R agonists (Adapted from references [ 24 ] ).CC BY · PubMed Central
Figure 3 Intracellular signaling pathways of GLP-1R in the cardiomyocytes (Adapted from references [ 36 , 39 ] ).
Figure 3 Intracellular signaling pathways of GLP-1R in the cardiomyocytes (Adapted from references [ 36 , 39 ] ).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 83 references

Cited by

See all 144

Metadata

Authors
Saraiva, F. K., & Sposito, A. C.
Affiliations
  • Pontifícia Universidade Católica de Campinas (BR)
  • Universidade Estadual de Campinas (UNICAMP) (BR)
Corresponding author
Sposito, Andrei C
Venue
Cardiovascular Diabetology
Published
2014-10-22
Volume
13
Issue
1
Pages
142-142
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2115692972
Cited by
143
References
83
Citations by year
2026: 13 · 2025: 14 · 2024: 9 · 2023: 9 · 2022: 8 · 2021: 19 · 2020: 7 · 2019: 16 · 2018: 12 · 2017: 18 · 2016: 9 · 2015: 8 · 2014: 1
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (300313/2007-1)
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
GLP-1 receptor agonists, cardiovascular effects, type 2 diabetes, cardiovascular risk, myocardial infarction, stroke, secondary prevention, statins, LDL cholesterol, anti-inflammatory activity, hepatic steatosis, insulin sensitivity, weight loss, satiety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Animals, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Receptors, Glucagon, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. https://app.cochat.ai/papers/10.1186/s12933-014-0142-7
The paper
Saraiva, F. K., & Sposito, A. C. (2014). Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-014-0142-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.